Skip to main content

Advertisement

SpringerLink
Log in

A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background Historically, sulfasalazine (SSZ) and 5-aminosalicylates (5-ASAs) have been a mainstay of mild-to-moderate ulcerative colitis (UC) remission induction and maintenance therapy. Considering the pivotal role of intestinal microbial flora in pathophysiology of UC and antimicrobial activity of sulfapyridine, we hypothesized that SSZ might be more effective than 5-ASAs in the management of UC. Aim To compare the efficacy and tolerability of SSZ with each of the 5-ASAs (mesalamine, olsalazine, and balsalazide) by a meta-analysis technique. Methods Pubmed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials were searched for studies compared efficacy and/or tolerability of SSZ with 5-ASAs in the management of UC. The search terms were: “sulfasalazine” or “sulfasalazine” and “5-aminosalicylic acid,” “mesalazine,” “mesalamine,” “olsalazine” or “balsalazide” and “ulcerative colitis.” Data were collected from 1966 to April 2008. There was no language restriction. “Overall improvement,” “relapse rate,” “total adverse events,” and “withdrawals because of adverse events” were the key outcomes of interest. Results Twenty randomized placebo controlled trials met our criteria and were included in the meta-analysis. Comparison of SSZ with mesalamine yielded a nonsignificant relative risk (RR) of 1.04 (95% confidence interval of 0.89–1.21, P = 0.63) for overall improvement, a nonsignificant RR of 0.98 (95% CI 0.78–1.23, P = 0.85) for relapse, a nonsignificant RR of 0.76 (95% CI 0.54–1.07, P = 0.11) for any adverse events, and a nonsignificant RR of 0.78 (95% CI 0.46–1.3, P = 0.33) for withdrawals due to adverse events. Comparison of SSZ with olsalazine yielded a nonsignificant RR of 1.14 (95% CI 0.91–1.43, P = 0.25) for overall improvement, a nonsignificant RR of 0.93 (95% CI 0.77–1.12, P = 0.42) for relapse, a nonsignificant RR of 1.21 (95% CI 0.9–1.61, P = 0.20) for any adverse events, and a nonsignificant RR of 1.53 (95% CI 0.93–2.52, P = 0.09) for withdrawals due to adverse events. Comparison of SSZ with balsalazide yielded a nonsignificant RR of 1.3 (95% CI 0.93–1.81, P = 0.12) for overall improvement, and a significant RR of 0.17 (95% CI 0.06–0.49, P = 0.001) for withdrawals because of adverse events. Conclusion SSZ does not differ from mesalamine or olsalazine in terms of efficacy and tolerability in UC. Withdrawal from study due to adverse events was significantly lower for balsalazide compared with SSZ. Convincing conclusions on the comparison of effectiveness and safety of balsalazide and SSZ in UC remains to be elucidated by further clinical trials. Considering the lower cost of treatment with SSZ and the equal rate of adverse events with other 5-ASAa, it is not surprising to suggest SSZ as a first-choice treatment for UC and reserve 5-ASAs for when SSZ intolerability occurs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  1. Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol. 2004;38:741–745. doi:10.1097/01.mcg.0000140188.88275.65.

    Article  PubMed  CAS  Google Scholar 

  2. Kucharzik T, Maaser C, Lügering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006;12:1068–1083. doi:10.1097/01.mib.0000235827.21778.d5.

    Article  PubMed  Google Scholar 

  3. Rezaie A, Khalaj S, Shabihkhani M, et al. Study on the correlations among disease activity index and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci. 2007;1095:305–314. doi:10.1196/annals.1397.034.

    Article  PubMed  CAS  Google Scholar 

  4. Rahimi R, Nikfar S, Abdollahi M. Meta analysis technique confirms the effectiveness of anti-TNFa in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit. 2007;13:PI13–PI18.

    PubMed  CAS  Google Scholar 

  5. Rahimi R, Nikfar S, Abdollahi M. Do anti tumor necrosis factors induce response and remission in patients with acute refractory crohn’s disease? A meta-analysis of controlled clinical trials. Biomed Pharmacother. 2007;61:75–80. doi:10.1016/j.biopha.2006.06.022.

    Article  PubMed  CAS  Google Scholar 

  6. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007;52:2015–2021. doi:10.1007/s10620-006-9622-2.

    Article  PubMed  Google Scholar 

  7. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci. 2004;49:1752–1757. doi:10.1007/s10620-004-9564-5.

    Article  PubMed  CAS  Google Scholar 

  8. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008;27:S15–S21.

    Google Scholar 

  9. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25:271–275. doi:10.1016/j.reprotox.2007.11.010.

    Article  PubMed  CAS  Google Scholar 

  10. Dallegri F, Ottonello L, Ballestrero A, Bogliolo F, Ferrando F, Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut. 1990;31:184–186. doi:10.1136/gut.31.2.184.

    Article  PubMed  CAS  Google Scholar 

  11. Miles AM, Grisham MB. Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis. Adv Exp Med Biol. 1995;371B:1317–1321.

    PubMed  CAS  Google Scholar 

  12. Travis SP, Jewell DP. Salicylates for ulcerative colitis–their mode of action. Pharmacol Ther. 1994;63:135–161. doi:10.1016/0163-7258(94)90042-6.

    Article  PubMed  CAS  Google Scholar 

  13. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid—new evidence. Aliment Pharmacol Ther. 2006;241:S2–S9. doi:10.1111/j.1365-2036.2006.03069.x.

    Article  Google Scholar 

  14. Bat B, Lodowska J, Orchel A, et al. Evaluation of biotransformation of sulfasalazine in the colon epithelial Caco-2 cells. Acta Pol Pharm. 2004;61:S8–S10.

    Google Scholar 

  15. Sartor RB. Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther. 1997;11:S17–S22. doi:10.1046/j.1365-2036.1997.90262000.x.

    Article  Google Scholar 

  16. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54. doi:10.1053/gast.2002.30294.

    Article  PubMed  Google Scholar 

  17. Gionchetti P, Rizzello F, Lammers KM, et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol. 2006;12:3306–3313.

    PubMed  CAS  Google Scholar 

  18. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52:2920–2925. doi:10.1007/s10620-007-9760-1.

    Article  PubMed  CAS  Google Scholar 

  19. Jadad A. Randomised controlled trials. London: BMJ; 1998.

    Google Scholar 

  20. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.

    PubMed  CAS  Google Scholar 

  21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101. doi:10.2307/2533446.

    Article  PubMed  CAS  Google Scholar 

  22. Manfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther. 2002;16:69–77. doi:10.1046/j.1365-2036.2002.01151.x.

    Article  Google Scholar 

  23. Green JR, Manfieldd JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther. 2002;16:61–68. doi:10.1046/j.1365-2036.2002.01150.x.

    Article  PubMed  CAS  Google Scholar 

  24. Ardizzone S, Petrillo M, Molteni P, Desideri S, Bianchi Porro G. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol. 1995;21:287–289. doi:10.1097/00004836-199512000-00007.

    Article  PubMed  CAS  Google Scholar 

  25. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine versus sulfasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol. 1995;7:391–396.

    PubMed  CAS  Google Scholar 

  26. Nilsson A, Danielsson A, Löfberg R, et al. Olsalazine versus sulfasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol. 1995;90:381–387.

    PubMed  CAS  Google Scholar 

  27. Rijk MC, van Lier HJ, van Tongeren JH. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Am J Gastroenterol. 1992;87:438–442.

    PubMed  CAS  Google Scholar 

  28. Kiilerich S, Ladefoged K, Rannem T, Ranløv PJ. Prophylactic effects of olsalazine vs. sulfasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut. 1992;33:252–255. doi:10.1136/gut.33.2.252.

    Article  PubMed  CAS  Google Scholar 

  29. Eliakim R, Wengrower D, Ligumsky M, Rachmilewitz D. Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission. Isr J Med Sci. 1990;26:47–49.

    PubMed  CAS  Google Scholar 

  30. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulfasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther. 1989;3:183–191.

    PubMed  CAS  Google Scholar 

  31. Rachmilewitz D. Coated mesalamine (5-aminosalicylic acid) versus sulfasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82–86.

    Article  PubMed  CAS  Google Scholar 

  32. Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulfasalazine in first attacks of ulcerative colitis? A double blind study. Gut. 1989;30:675–679. doi:10.1136/gut.30.5.675.

    Article  PubMed  CAS  Google Scholar 

  33. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988;29:835–837. doi:10.1136/gut.29.6.835.

    Article  PubMed  CAS  Google Scholar 

  34. Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of olsalazine and sulfasalazine in active ulcerative colitis. Scand J Gastroenterol Suppl. 1988;148:40–44. doi:10.3109/00365528809101546.

    Article  PubMed  CAS  Google Scholar 

  35. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulfasalazine. Aliment Pharmacol Ther. 1988;2:237–243.

    Article  PubMed  CAS  Google Scholar 

  36. Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology. 1988;95:1449–1453.

    PubMed  CAS  Google Scholar 

  37. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalamine) and sulfasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988;29:669–674. doi:10.1136/gut.29.5.669.

    Article  PubMed  CAS  Google Scholar 

  38. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalamine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383–1389.

    PubMed  CAS  Google Scholar 

  39. Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalamine tablets in the treatment of active ulcerative colitis. J Gastroenterol. 1995;30l8:S108–S111.

    Google Scholar 

  40. Andreoli A, Cosintino R, Trotti R, Berri F, Prantera C. 5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission [abstract]. Clin Controversies Inflamm Bowel Dis. 1987;170.

  41. Jiang XL, Cui HF. Different therapy for different types of ulcerative colitis. World J Gastroenterol. 2004;10:1513–1520.

    PubMed  Google Scholar 

  42. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28:1983–1988. doi:10.1016/j.clinthera.2006.12.012.

    Article  PubMed  CAS  Google Scholar 

  43. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006;24:37–40. doi:10.1111/j.1365-2036.2006.03058.x.

    Article  PubMed  CAS  Google Scholar 

  44. Ransford RA, Langman MJ. Sulfasalazine and mesalamine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut. 2005;51:536–539. doi:10.1136/gut.51.4.536.

    Article  Google Scholar 

  45. Mahmud N, Weir DG, Kelleher D. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. Ir J Med Sci. 1999;168:228–232.

    Article  PubMed  CAS  Google Scholar 

  46. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;19:CD000543.

    Google Scholar 

  47. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;19:CD000544.

    Google Scholar 

  48. British National Formulary. London: BMJ Publishing Group; 2006;54–55.

  49. Walker AM, Szneke P, Bianchi LA, Field LG, Sutherland LR, Dreyer NA. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol. 1997;92:816–820.

    PubMed  CAS  Google Scholar 

  50. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci. 2008 Jul 10. [Epub ahead of print].

  51. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci. 2008 Feb 14. [Epub ahead of print].

  52. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 2008;53:1278–1284. doi:10.1007/s10620-007-0006-z.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

There was no financial support for this study and the authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Drug Selecting Committee, Food & Drug Organization, and Food & Drug Laboratory Research Center, Ministry of Health and Medical Education, Tehran, Iran

    Shekoufeh Nikfar

  2. Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences (TUMS), Tehran, 14155-6451, Iran

    Roja Rahimi & Mohammad Abdollahi

  3. Faculty of Medicine, University of Alberta, Edmonton, Canada

    Ali Rezaie

Authors
  1. Shekoufeh Nikfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roja Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Rezaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Abdollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Abdollahi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nikfar, S., Rahimi, R., Rezaie, A. et al. A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis. Dig Dis Sci 54, 1157–1170 (2009). https://doi.org/10.1007/s10620-008-0481-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0481-x

Keywords

Search

Navigation